If we have any methods to widen CI in parallel design with high variance drug? [RSABE / ABEL]

posted by ElMaestro  – Denmark, 2021-02-02 12:12 (1615 d 08:56 ago) – Posting: # 22200
Views: 3,152

Hi libaiyi,

❝ (...) So my quesion is if we have any method to widen the CI like RSABE in cross-over study?


I don't think there is any authority generally willing to widen the acceptance range in parallel trials involving humans (they'd perhaps do it if you were studying pMDI's in vitro etc).

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,677 registered users;
34 visitors (0 registered, 34 guests [including 6 identified bots]).
Forum time: 22:09 CEST (Europe/Vienna)

Many people tend to look at programming styles and languages like religions:
if you belong to one, you cannot belong to others.
But this analogy is another fallacy.    Niklaus Wirth

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5